Systematic annotation and analysis of "virmugens" -Virulence factors whose mutants can be used as live attenuated vaccines

Vaccine

Volumn 31, Issue 5, 2013, Pages 797-805

  Racz, Rebecca ^a   Chung, Monica ^a   Xiang, Zuoshuang ^b   He, Yongqun ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Bacteria; Bioinformatics; Database; Live attenuated vaccine; Meta analysis; Protozoa; Virmugen; Virulence factor; Virus

Indexed keywords

AROA PROTEIN; BACTERIAL PROTEIN; GLYCOPROTEIN D; GLYCOPROTEIN E; GLYCOPROTEIN E1; GLYCOPROTEIN E2; GLYCOPROTEIN H; GLYCOPROTEIN I; LIVE VACCINE; OUTER MEMBRANE PROTEIN; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ARTICLE; BRUCELLA; CELL MEMBRANE; GENE EXPRESSION; IMMUNITY; NONHUMAN; NUCLEOTIDE TRANSPORT; PASTEURELLA; PHYLOGENETIC TREE; PRIORITY JOURNAL; SALMONELLA; SEQUENCE ALIGNMENT; SHIGELLA; STAPHYLOCOCCUS; WILD TYPE; YERSINIA;

ANIMALS; BACTERIAL VACCINES; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; GENE KNOCKOUT TECHNIQUES; HUMANS; PROTOZOAN VACCINES; VACCINES, ATTENUATED; VIRAL VACCINES; VIRULENCE FACTORS;

EID: 84872603820     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.066     Document Type: Article

References (46)

1. Casadevall A., Pirofski L.A. Virulence factors and their mechanisms of action: the view from a damage-response framework. J Water Health 2009, 7(Suppl. 1):S2-S18.
2. Brinkman R.R., Courtot M., Derom D., Fostel J., He Y., Lord P., et al. Modeling biomedical experimental processes with OBI. J Biomed Semantics 2010, (June (1 Suppl. 1)):S7. 10.1186/2041-1480-1-S1-S7.
3. Richt J.A., Garcia-Sastre A. Attenuated influenza virus vaccines with modified NS1 proteins. Curr Top Microbiol Immunol 2009, 333:177-195.
4. Xiang Z., Todd T., Ku K.P., Kovacic B.L., Larson C.B., Chen F., et al. VIOLIN: vaccine investigation and online information network. Nucleic Acids Res 2008, 36(January (Database issue)):D923-D928.
5. Xiang Z., Zheng W., He Y. BBP: Brucella genome annotation with literature mining and curation. BMC Bioinform 2006, 7(July (1)):347.
6. Yang B., Sayers S., Xiang Z., He Y. Protegen: a web-based protective antigen database and analysis system. Nucleic Acids Res 2011, 39(January):D1073-D1078. (Database issue). http://www.ncbi.nlm.nih.gov/pubmed/20959289.
7. Larkin M.A., Blackshields G., Brown N.P., Chenna R., McGettigan P.A., McWilliam H., et al. Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23(November (21)):2947-2948.
8. Tamura K., Dudley J., Nei M., Kumar S. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24(August (8)):1596-1599.
9. Saitou N., Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987, 4(July (4)):406-425.
10. Shayman J.A., Kelly R., Kollmeyer J., He Y., Abe A. Group XV phospholipase A, a lysosomal phospholipase A. Prog Lipid Res 2011, 50(January (1)):1-13.
11. He Y., Cowell L., Diehl A.D., Mobley H.L., Peters B., Ruttenberg A., et al. VO: vaccine ontology. The 1st International Conference on Biomedical Ontology (ICBO 2009) Nature Precedings 2009, http://precedingsnaturecom/documents/3553/version/1.
12. Ozgur A., Xiang Z., Radev D., He Y. Mining of vaccine-associated IFN-γ gene interaction networks using the vaccine ontology. J Biomed Semantics 2011, 2(May (Suppl. 2)):S8. http://www.ncbi.nlm.nih.gov/pubmed/21624163.
13. Xiang Z., Courtot M., Brinkman R.R., Ruttenberg A., He Y. OntoFox: web-based support for ontology reuse. BMC Res Notes 2010, 3:175.
14. Stevenson A., Roberts M. Use of a rationally attenuated Bordetella bronchiseptica as a live mucosal vaccine and vector for heterologous antigens. Vaccine 2002, 20(May (17-18)):2325-2335.
15. Dagleish M.P., Hodgson J.C., Ataei S., Finucane A., Finlayson J., Sales J., et al. Safety and protective efficacy of intramuscular vaccination with a live aroA derivative of Pasteurella multocida B:2 against experimental hemorrhagic septicemia in calves. Infect Immun 2007, 75(December (12)):5837-5844.
16. Dougan G., Maskell D., Pickard D., Hormaeche C. Isolation of stable aroA mutants of Salmonella typhi Ty2: properties and preliminary characterisation in mice. Mol Gen Genet 1987, 207(May (2-3)):402-405.
17. Noriega F.R., Wang J.Y., Losonsky G., Maneval D.R., Hone D.M., Levine M.M. Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine. Infect Immun 1994, 62(November (11)):5168-5172.
18. Buzzola F.R., Barbagelata M.S., Caccuri R.L., Sordelli D.O. Attenuation and persistence of and ability to induce protective immunity to a Staphylococcus aureus aroA mutant in mice. Infect Immun 2006, 74(June (6)):3498-3506.
19. Bowe F., O'Gaora P., Maskell D., Cafferkey M., Dougan G. Virulence, persistence, and immunogenicity of Yersinia enterocolitica O:8 aroA mutants. Infect Immun 1989, 57(October (10)):3234-3236.
20. Tacket C.O., Levine M.M. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin Infect Dis 2007, 45(July (Suppl. 1)):S20-S23.
21. Karnell A., Cam P.D., Verma N., Lindberg A.A. AroD deletion attenuates Shigella flexneri strain 2457T and makes it a safe and efficacious oral vaccine in monkeys. Vaccine 1993, 11(8):830-836.
22. Srilunchang T., Proungvitaya T., Wongratanacheewin S., Strugnell R., Homchampa P. Construction and characterization of an unmarked aroC deletion mutant of Burkholderia pseudomallei strain A2. Southeast Asian J Trop Med Public Health 2009, 40(January (1)):123-130.
23. Xiao J., Chen T., Wang Q., Liu Q., Wang X., Lv Y., et al. Search for live attenuated vaccine candidate against edwardsiellosis by mutating virulence-related genes of fish pathogen Edwardsiella tarda. Lett Appl Microbiol 2011, 53(October (4)):430-437.
24. Sebkova A., Karasova D., Crhanova M., Budinska E., Rychlik I. aro mutations in Salmonella enterica cause defects in cell wall and outer membrane integrity. J Bacteriol 2008, 190(May (9)):3155-3160.
25. McClelland M., Sanderson K.E., Spieth J., Clifton S.W., Latreille P., Courtney L., et al. Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature 2001, 413(October (6858)):852-856.
26. Ficht T.A., Kahl-McDonagh M.M., Arenas-Gamboa A.M., Rice-Ficht A.C. Brucellosis: the case for live, attenuated vaccines. Vaccine 2009, 27(November (Suppl. 4)):D40-D43.
27. Field H.J., Wildy P. The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J Hyg (Lond) 1978, 81(October (2)):267-277.
28. Slater J.D., Gibson J.S., Field H.J. Pathogenicity of a thymidine kinase-deficient mutant of equine herpesvirus 1 in mice and specific pathogen-free foals. J Gen Virol 1993, 74(May (Pt 5)):819-828.
29. Weigel R.M., Hahn E.C., Scherba G. Survival and immunization of raccoons after exposure to pseudorabies (Aujeszky's disease) virus gene-deleted vaccines. Vet Microbiol 2003, 92(March (1-2)):19-24.
30. Yokoyama N., Maeda K., Tohya Y., Kawaguchi Y., Shin Y.S., Ono M., et al. Pathogenicity and vaccine efficacy of a thymidine kinase-deficient mutant of feline herpesvirus type 1 in cats. Arch Virol 1996, 141(3-4):481-494.
31. Han M.G., Kweon C.H., Mo I.P., Kim S.J. Pathogenicity and vaccine efficacy of a thymidine kinase gene deleted infectious laryngotracheitis virus expressing the green fluorescent protein gene. Arch Virol 2002, 147(May (5)):1017-1031.
32. Li J., Le L., Sibley D.A., Mathis J.M., Curiel D.T. Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion. Virology 2005, 338(August (2)):247-258.
33. Zimmermann W., Broll H., Ehlers B., Buhk H.J., Rosenthal A., Goltz M. Genome sequence of bovine herpesvirus 4, a bovine Rhadinovirus, and identification of an origin of DNA replication. J Virol 2001, 75(February (3)):1186-1194.
34. Spiro R.G. Glycoproteins: structure, metabolism and biology. N Engl J Med 1963, 269(September):616-621. CONCL.
35. Rodriguez L., Cuesta I., Asenjo A., Villanueva N. Human respiratory syncytial virus matrix protein is an RNA-binding protein: binding properties, location and identity of the RNA contact residues. J Gen Virol 2004, 85(March (Pt 3)):709-719.
36. Pham Q.N., Biacchesi S., Skiadopoulos M.H., Murphy B.R., Collins P.L., Buchholz U.J. Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo. J Virol 2005, 79(December (24)):15114-15122.
37. Huynh M.H., Carruthers V.B. Toxoplasma MIC2 is a major determinant of invasion and virulence. PLoS Pathog 2006, 2(August (8)):e84.
38. Hernandez Pando R., Aguilar L.D., Smith I., Manganelli R Immunogenicity and protection induced by a Mycobacterium tuberculosis sigE mutant in a BALB/c mouse model of progressive pulmonary tuberculosis. Infect Immun 2010, 78(July (7)):3168-3176.
39. Aguilar L.D., Infante E., Bianco M.V., Cataldi A., Bigi F., Pando R.H. Immunogenicity and protection induced by Mycobacterium tuberculosis mce-2 and mce-3 mutants in a Balb/c mouse model of progressive pulmonary tuberculosis. Vaccine 2006, 24(March (13)):2333-2342.
40. Darji A., Mohamed W., Domann E., Chakraborty T. Induction of immune responses by attenuated isogenic mutant strains of Listeria monocytogenes. Vaccine 2003, 21(June (Suppl. 2)):S102-S109.
41. Jayakar H.R., Parvathareddy J., Fitzpatrick E.A., Bina X.R., Bina J.E., Re F., et al. A galU mutant of Francisella tularensis is attenuated for virulence in a murine pulmonary model of tularemia. BMC Microbiol 2011, 11:179.
42. Sammons-Jackson W.L., McClelland K., Manch-Citron J.N., Metzger D.W., Bakshi C.S., Garcia E., et al. Generation and characterization of an attenuated mutant in a response regulator gene of Francisella tularensis live vaccine strain (LVS). DNA Cell Biol 2008, 27(July (7)):387-403.
43. Kahl-McDonagh M.M., Arenas-Gamboa A.M., Ficht T.A. Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge. Infect Immun 2007, 75(October (10)):4923-4932.
44. Kock C., Beineke A., Seitz M., Ganter M., Waldmann K.H., Valentin-Weigand P., et al. Intranasal immunization with a live Streptococcus suis isogenic ofs mutant elicited suilysin-neutralization titers but failed to induce opsonizing antibodies and protection. Vet Immunol Immunopathol 2009, 132(December (2-4)):135-145.
45. Haijema B.J., Volders H., Rottier P.J. Live, attenuated coronavirus vaccines through the directed deletion of group-specific genes provide protection against feline infectious peritonitis. J Virol 2004, 78(April (8)):3863-3871.
46. He Y., Xiang Z., Mobley H.L. Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development. J Biomed Biotechnol 2010, 2010:15. Article ID 297505.